AB0864 Extensive evaluation of biomarkers related with bone turnover in patients with ankylosing spondylitis

Background Ankylosing spondylitis (AS) is a chronic inflammatory disease of spine and sacroiliac joints and characterized by new bone formation. Osteoporosis is also accompanied with AS.Human nuclear factor κβ ligand (RANKL) stimulate osteoclasts. Osteoprotegrin (OPG), which is produced by osteoblas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.688
Hauptverfasser: Taylan, A., Sari, I., Akinci, B., Bilge, S., Kozaci, D.L., Akar, S., Yalcin, H., Gunay, N., Akkoc, N.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Suppl 3
container_start_page 688
container_title Annals of the rheumatic diseases
container_volume 71
creator Taylan, A.
Sari, I.
Akinci, B.
Bilge, S.
Kozaci, D.L.
Akar, S.
Yalcin, H.
Gunay, N.
Akkoc, N.
description Background Ankylosing spondylitis (AS) is a chronic inflammatory disease of spine and sacroiliac joints and characterized by new bone formation. Osteoporosis is also accompanied with AS.Human nuclear factor κβ ligand (RANKL) stimulate osteoclasts. Osteoprotegrin (OPG), which is produced by osteoblasts, inhibits RANKL and plays an important role in bone formation. The Wnt signaling cascade and the secreted inhibitor of Wnts, Sclerostin, Dickkopfs (Dkks) and secreted frizzled related proteins (sFRP1) play important roles in bone turnover Objectives We investigated changes in bone mineral density (BMD) and the levels of various biomarkers related with bone turnover with regard to clinical parameters, disease activity and treatment regimen with/without anti TNFα drugs. Methods Fifty five AS patients (48Males) and 33 controls (24Males) were included in the study. Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index (BASMI) and radiologic changes were scored by bath ankylosing spondylitis radiologic index (BASRI). Patients were also evaluated with the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).BMD of hip and spine and various bone turnover biomarkers were measured. Results: Table 1. Clinical and laboratory characteristics of the patients and controls AS patients (n=55)Controls (n=33)P value IL-6 (pg/mL)18.5 (5-5458.1(4-69)0.0001 IFNo(pg/ml)0.002 (0.002-1.956)0.002 (0.002-0.956)0.5 BAP (U/L)29 (13-107)26 (2-51)0.1 Calcium (mg/dl)10 (9-11)9.9 (9,3-11)0.6 Phosphor (mg/dl)1.3 (1.7-4.7)3.4 (2,2-4,5)0.9 Vitamin D (nM)87 (4-266)102 (10-303)0.5 NTX (nM BCE)82 (52-188)84 (57-106)0.3 TRAP(U/L)3.76 (2.25-6.55)3.66 (2.31-8.34)0.3 PTH (pg/mL)45 (44-170)77 (45-180)0.01 RANKL (pmol/L)284 (101-1598)292 (143-783)0.7 OPG (pg/mL)339 (52-1118)527(16-1030)0.02 Sklerostin (pmol/L)73 (48-126)77.1 (49-110)0.1 sFrp1 (ng/ml)0.1 (0-17)0.2 (0-1)0.3 DKK1(pg/mL)97 (17-771)115 (29-278)0.6 Conclusions OPG was lower and correlated with active disease state in AS patients. Wnt signal pathway inhibitors level did not altered in AS and ongoing ectopic bone formation may be related dysfunction of these molecules at cellular level.There is a complex interaction of anti TNF α drug with various cytokines. OPG is decreased but Dkk1 is increased on anti TNF α treatment in AS patients. Even clues of the osteoblastic effects of anti TNF α treatment, concrete role of these drugs both on osteoporosis and
doi_str_mv 10.1136/annrheumdis-2012-eular.864
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777973045</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008655051</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1635-618e0e7cf825dc65875a479b9438a9460d949f49ba0c0aafa1abdfbc0f0c93fe3</originalsourceid><addsrcrecordid>eNqVkEFPHCEUx0mjiavtdyD1PBYWBobe3I2tJqY9VNveCDPzqKyzsAKzdW9e-kX7SYpOY7x6IvB-f957P4TeU3JCKRMfjPfxBsZ171I1J3RewTiYeNII_gbNKBdNeRVkD80IIaziSsgDdJjSqlxJQ5sZ8qcLUui_D3_O7jP45LaAYWuG0WQXPA4Wty6sTbyFmHCEwWTo8W-Xb3AbPOA8Rh-2ELHzeFMi4HOaysbf7oaQnP-F0yb4fje47NJbtG_NkODd__MIXX86u1qeV5dfP18sTy-rlgpWV4I2QEB2tpnXfSfqRtaGS9UqzhqjuCC94spy1RrSEWOsoabtbdsRSzrFLLAjdDz9u4nhboSU9SqUUUtLTaWUSjLC60J9nKguhpQiWL2Jriy705ToR7_6hV_96Fc_-dXFWAlXU9ilDPfPyaJKC8lkrb98X-rF4sf827n4qVnh64lv16vX9PkHmLmZKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777973045</pqid></control><display><type>article</type><title>AB0864 Extensive evaluation of biomarkers related with bone turnover in patients with ankylosing spondylitis</title><source>BMJ Journals - NESLi2</source><creator>Taylan, A. ; Sari, I. ; Akinci, B. ; Bilge, S. ; Kozaci, D.L. ; Akar, S. ; Yalcin, H. ; Gunay, N. ; Akkoc, N.</creator><creatorcontrib>Taylan, A. ; Sari, I. ; Akinci, B. ; Bilge, S. ; Kozaci, D.L. ; Akar, S. ; Yalcin, H. ; Gunay, N. ; Akkoc, N.</creatorcontrib><description>Background Ankylosing spondylitis (AS) is a chronic inflammatory disease of spine and sacroiliac joints and characterized by new bone formation. Osteoporosis is also accompanied with AS.Human nuclear factor κβ ligand (RANKL) stimulate osteoclasts. Osteoprotegrin (OPG), which is produced by osteoblasts, inhibits RANKL and plays an important role in bone formation. The Wnt signaling cascade and the secreted inhibitor of Wnts, Sclerostin, Dickkopfs (Dkks) and secreted frizzled related proteins (sFRP1) play important roles in bone turnover Objectives We investigated changes in bone mineral density (BMD) and the levels of various biomarkers related with bone turnover with regard to clinical parameters, disease activity and treatment regimen with/without anti TNFα drugs. Methods Fifty five AS patients (48Males) and 33 controls (24Males) were included in the study. Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index (BASMI) and radiologic changes were scored by bath ankylosing spondylitis radiologic index (BASRI). Patients were also evaluated with the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).BMD of hip and spine and various bone turnover biomarkers were measured. Results: Table 1. Clinical and laboratory characteristics of the patients and controls AS patients (n=55)Controls (n=33)P value IL-6 (pg/mL)18.5 (5-5458.1(4-69)0.0001 IFNo(pg/ml)0.002 (0.002-1.956)0.002 (0.002-0.956)0.5 BAP (U/L)29 (13-107)26 (2-51)0.1 Calcium (mg/dl)10 (9-11)9.9 (9,3-11)0.6 Phosphor (mg/dl)1.3 (1.7-4.7)3.4 (2,2-4,5)0.9 Vitamin D (nM)87 (4-266)102 (10-303)0.5 NTX (nM BCE)82 (52-188)84 (57-106)0.3 TRAP(U/L)3.76 (2.25-6.55)3.66 (2.31-8.34)0.3 PTH (pg/mL)45 (44-170)77 (45-180)0.01 RANKL (pmol/L)284 (101-1598)292 (143-783)0.7 OPG (pg/mL)339 (52-1118)527(16-1030)0.02 Sklerostin (pmol/L)73 (48-126)77.1 (49-110)0.1 sFrp1 (ng/ml)0.1 (0-17)0.2 (0-1)0.3 DKK1(pg/mL)97 (17-771)115 (29-278)0.6 Conclusions OPG was lower and correlated with active disease state in AS patients. Wnt signal pathway inhibitors level did not altered in AS and ongoing ectopic bone formation may be related dysfunction of these molecules at cellular level.There is a complex interaction of anti TNF α drug with various cytokines. OPG is decreased but Dkk1 is increased on anti TNF α treatment in AS patients. Even clues of the osteoblastic effects of anti TNF α treatment, concrete role of these drugs both on osteoporosis and ectopic bone formation still need to be clarified. Disclosure of Interest None Declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2012-eular.864</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.688</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/71/Suppl_3/688.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/71/Suppl_3/688.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3187,23562,27915,27916,77361,77392</link.rule.ids></links><search><creatorcontrib>Taylan, A.</creatorcontrib><creatorcontrib>Sari, I.</creatorcontrib><creatorcontrib>Akinci, B.</creatorcontrib><creatorcontrib>Bilge, S.</creatorcontrib><creatorcontrib>Kozaci, D.L.</creatorcontrib><creatorcontrib>Akar, S.</creatorcontrib><creatorcontrib>Yalcin, H.</creatorcontrib><creatorcontrib>Gunay, N.</creatorcontrib><creatorcontrib>Akkoc, N.</creatorcontrib><title>AB0864 Extensive evaluation of biomarkers related with bone turnover in patients with ankylosing spondylitis</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background Ankylosing spondylitis (AS) is a chronic inflammatory disease of spine and sacroiliac joints and characterized by new bone formation. Osteoporosis is also accompanied with AS.Human nuclear factor κβ ligand (RANKL) stimulate osteoclasts. Osteoprotegrin (OPG), which is produced by osteoblasts, inhibits RANKL and plays an important role in bone formation. The Wnt signaling cascade and the secreted inhibitor of Wnts, Sclerostin, Dickkopfs (Dkks) and secreted frizzled related proteins (sFRP1) play important roles in bone turnover Objectives We investigated changes in bone mineral density (BMD) and the levels of various biomarkers related with bone turnover with regard to clinical parameters, disease activity and treatment regimen with/without anti TNFα drugs. Methods Fifty five AS patients (48Males) and 33 controls (24Males) were included in the study. Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index (BASMI) and radiologic changes were scored by bath ankylosing spondylitis radiologic index (BASRI). Patients were also evaluated with the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).BMD of hip and spine and various bone turnover biomarkers were measured. Results: Table 1. Clinical and laboratory characteristics of the patients and controls AS patients (n=55)Controls (n=33)P value IL-6 (pg/mL)18.5 (5-5458.1(4-69)0.0001 IFNo(pg/ml)0.002 (0.002-1.956)0.002 (0.002-0.956)0.5 BAP (U/L)29 (13-107)26 (2-51)0.1 Calcium (mg/dl)10 (9-11)9.9 (9,3-11)0.6 Phosphor (mg/dl)1.3 (1.7-4.7)3.4 (2,2-4,5)0.9 Vitamin D (nM)87 (4-266)102 (10-303)0.5 NTX (nM BCE)82 (52-188)84 (57-106)0.3 TRAP(U/L)3.76 (2.25-6.55)3.66 (2.31-8.34)0.3 PTH (pg/mL)45 (44-170)77 (45-180)0.01 RANKL (pmol/L)284 (101-1598)292 (143-783)0.7 OPG (pg/mL)339 (52-1118)527(16-1030)0.02 Sklerostin (pmol/L)73 (48-126)77.1 (49-110)0.1 sFrp1 (ng/ml)0.1 (0-17)0.2 (0-1)0.3 DKK1(pg/mL)97 (17-771)115 (29-278)0.6 Conclusions OPG was lower and correlated with active disease state in AS patients. Wnt signal pathway inhibitors level did not altered in AS and ongoing ectopic bone formation may be related dysfunction of these molecules at cellular level.There is a complex interaction of anti TNF α drug with various cytokines. OPG is decreased but Dkk1 is increased on anti TNF α treatment in AS patients. Even clues of the osteoblastic effects of anti TNF α treatment, concrete role of these drugs both on osteoporosis and ectopic bone formation still need to be clarified. Disclosure of Interest None Declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkEFPHCEUx0mjiavtdyD1PBYWBobe3I2tJqY9VNveCDPzqKyzsAKzdW9e-kX7SYpOY7x6IvB-f957P4TeU3JCKRMfjPfxBsZ171I1J3RewTiYeNII_gbNKBdNeRVkD80IIaziSsgDdJjSqlxJQ5sZ8qcLUui_D3_O7jP45LaAYWuG0WQXPA4Wty6sTbyFmHCEwWTo8W-Xb3AbPOA8Rh-2ELHzeFMi4HOaysbf7oaQnP-F0yb4fje47NJbtG_NkODd__MIXX86u1qeV5dfP18sTy-rlgpWV4I2QEB2tpnXfSfqRtaGS9UqzhqjuCC94spy1RrSEWOsoabtbdsRSzrFLLAjdDz9u4nhboSU9SqUUUtLTaWUSjLC60J9nKguhpQiWL2Jriy705ToR7_6hV_96Fc_-dXFWAlXU9ilDPfPyaJKC8lkrb98X-rF4sf827n4qVnh64lv16vX9PkHmLmZKw</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Taylan, A.</creator><creator>Sari, I.</creator><creator>Akinci, B.</creator><creator>Bilge, S.</creator><creator>Kozaci, D.L.</creator><creator>Akar, S.</creator><creator>Yalcin, H.</creator><creator>Gunay, N.</creator><creator>Akkoc, N.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20130601</creationdate><title>AB0864 Extensive evaluation of biomarkers related with bone turnover in patients with ankylosing spondylitis</title><author>Taylan, A. ; Sari, I. ; Akinci, B. ; Bilge, S. ; Kozaci, D.L. ; Akar, S. ; Yalcin, H. ; Gunay, N. ; Akkoc, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1635-618e0e7cf825dc65875a479b9438a9460d949f49ba0c0aafa1abdfbc0f0c93fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taylan, A.</creatorcontrib><creatorcontrib>Sari, I.</creatorcontrib><creatorcontrib>Akinci, B.</creatorcontrib><creatorcontrib>Bilge, S.</creatorcontrib><creatorcontrib>Kozaci, D.L.</creatorcontrib><creatorcontrib>Akar, S.</creatorcontrib><creatorcontrib>Yalcin, H.</creatorcontrib><creatorcontrib>Gunay, N.</creatorcontrib><creatorcontrib>Akkoc, N.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taylan, A.</au><au>Sari, I.</au><au>Akinci, B.</au><au>Bilge, S.</au><au>Kozaci, D.L.</au><au>Akar, S.</au><au>Yalcin, H.</au><au>Gunay, N.</au><au>Akkoc, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0864 Extensive evaluation of biomarkers related with bone turnover in patients with ankylosing spondylitis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>71</volume><issue>Suppl 3</issue><spage>688</spage><pages>688-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background Ankylosing spondylitis (AS) is a chronic inflammatory disease of spine and sacroiliac joints and characterized by new bone formation. Osteoporosis is also accompanied with AS.Human nuclear factor κβ ligand (RANKL) stimulate osteoclasts. Osteoprotegrin (OPG), which is produced by osteoblasts, inhibits RANKL and plays an important role in bone formation. The Wnt signaling cascade and the secreted inhibitor of Wnts, Sclerostin, Dickkopfs (Dkks) and secreted frizzled related proteins (sFRP1) play important roles in bone turnover Objectives We investigated changes in bone mineral density (BMD) and the levels of various biomarkers related with bone turnover with regard to clinical parameters, disease activity and treatment regimen with/without anti TNFα drugs. Methods Fifty five AS patients (48Males) and 33 controls (24Males) were included in the study. Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index (BASMI) and radiologic changes were scored by bath ankylosing spondylitis radiologic index (BASRI). Patients were also evaluated with the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).BMD of hip and spine and various bone turnover biomarkers were measured. Results: Table 1. Clinical and laboratory characteristics of the patients and controls AS patients (n=55)Controls (n=33)P value IL-6 (pg/mL)18.5 (5-5458.1(4-69)0.0001 IFNo(pg/ml)0.002 (0.002-1.956)0.002 (0.002-0.956)0.5 BAP (U/L)29 (13-107)26 (2-51)0.1 Calcium (mg/dl)10 (9-11)9.9 (9,3-11)0.6 Phosphor (mg/dl)1.3 (1.7-4.7)3.4 (2,2-4,5)0.9 Vitamin D (nM)87 (4-266)102 (10-303)0.5 NTX (nM BCE)82 (52-188)84 (57-106)0.3 TRAP(U/L)3.76 (2.25-6.55)3.66 (2.31-8.34)0.3 PTH (pg/mL)45 (44-170)77 (45-180)0.01 RANKL (pmol/L)284 (101-1598)292 (143-783)0.7 OPG (pg/mL)339 (52-1118)527(16-1030)0.02 Sklerostin (pmol/L)73 (48-126)77.1 (49-110)0.1 sFrp1 (ng/ml)0.1 (0-17)0.2 (0-1)0.3 DKK1(pg/mL)97 (17-771)115 (29-278)0.6 Conclusions OPG was lower and correlated with active disease state in AS patients. Wnt signal pathway inhibitors level did not altered in AS and ongoing ectopic bone formation may be related dysfunction of these molecules at cellular level.There is a complex interaction of anti TNF α drug with various cytokines. OPG is decreased but Dkk1 is increased on anti TNF α treatment in AS patients. Even clues of the osteoblastic effects of anti TNF α treatment, concrete role of these drugs both on osteoporosis and ectopic bone formation still need to be clarified. Disclosure of Interest None Declared</abstract><cop>Kidlington</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2012-eular.864</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.688
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1777973045
source BMJ Journals - NESLi2
title AB0864 Extensive evaluation of biomarkers related with bone turnover in patients with ankylosing spondylitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T01%3A04%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0864%E2%80%85Extensive%20evaluation%20of%20biomarkers%20related%20with%20bone%20turnover%20in%20patients%20with%20ankylosing%20spondylitis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Taylan,%20A.&rft.date=2013-06-01&rft.volume=71&rft.issue=Suppl%203&rft.spage=688&rft.pages=688-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2012-eular.864&rft_dat=%3Cproquest_cross%3E4008655051%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777973045&rft_id=info:pmid/&rfr_iscdi=true